Nattokinase for Heart Health

Every 34 seconds, someone in the United States dies of cardiovascular disease — making heart health one of the most urgently researched areas in medicine today.

Against that backdrop, nattokinase — a fibrinolytic enzyme derived from fermented soybeans — has attracted serious scientific attention over the past two decades. Researchers have investigated its ability to reduce blood pressure, dissolve arterial fibrin, inhibit platelet aggregation, and slow the progression of atherosclerosis. This article summarizes what the clinical evidence actually shows, what limitations researchers have identified, and what BioAbsorb Nattokinase offers for those looking to act on this research. For a complete overview of the enzyme itself, see our complete guide to nattokinase.

Table of Contents

1. The Cardiovascular Disease Burden: Why This Matters
2. How Nattokinase Targets Cardiovascular Risk
3. Blood Pressure: What the Clinical Trials Found
4. Atherosclerosis and Plaque: The 1,062-Participant Study
5. Anti-Inflammatory and Antioxidant Effects on the Heart
6. Limitations of the Research: What We Don't Know Yet
7. BioAbsorb Nattokinase — Delivery That Protects the Enzyme
8. Frequently Asked Questions
9. Conclusion

1. The Cardiovascular Disease Burden: Why This Matters

Cardiovascular disease is not one condition — it is a category that includes coronary artery disease, heart failure, hypertension, stroke, and peripheral artery disease. Together, these conditions account for approximately 19.8 million deaths worldwide in 2022, or roughly 32% of all global deaths. Of those, 85% were attributable to heart attack and stroke — events that, in many cases, were preceded by years of silent, progressive arterial damage.

The underlying biology of most cardiovascular events follows a predictable trajectory: arterial walls accumulate fibrin and lipid-laden plaque over time, blood clotting regulation becomes dysregulated, blood pressure rises, and at some threshold, a clot or arterial rupture triggers an acute event. Addressing any one of these upstream factors — fibrin accumulation, elevated blood pressure, platelet hyper-reactivity, or arterial inflammation — can meaningfully reduce event risk over the long term.

This is the context in which researchers have studied nattokinase. Not as a cure for heart disease, but as a natural compound with documented activity on several of these upstream risk factors simultaneously. Understanding the evidence requires looking at each mechanism separately — beginning with how the enzyme actually interacts with the cardiovascular system.

2. How Nattokinase Targets Cardiovascular Risk

Nattokinase is a serine protease — an enzyme that works by cleaving peptide bonds in proteins. Its cardiovascular relevance comes from at least four distinct but interconnected mechanisms, each of which has been characterized in laboratory and clinical research over the past two decades. Understanding how it works helps clarify both its promise and its limitations.

The primary mechanism is direct fibrinolysis: nattokinase degrades fibrin — the insoluble protein mesh that forms the structural framework of blood clots. But its fibrinolytic activity goes beyond direct fibrin degradation. Research in Integrative Medicine Insights identified that nattokinase cleaves and inactivates PAI-1 (plasminogen activator inhibitor-1) — the body's primary brake on its own fibrinolytic system. By removing this inhibitor, nattokinase amplifies the activity of tissue plasminogen activator (tPA), which in turn converts plasminogen into plasmin — the body's own clot-dissolving enzyme. The estimated fibrinolytic potency of nattokinase is approximately 4 times that of plasmin itself.

Beyond fibrinolysis, nattokinase inhibits platelet aggregation through effects on thromboxane B2 formation — reducing the tendency of platelets to clump together without producing the bleeding risk associated with anticoagulant drugs. A 2015 double-blind, placebo-controlled crossover study in 12 healthy men confirmed that a single 2,000 FU oral dose measurably enhanced fibrinolysis and anti-coagulation parameters within hours of ingestion. For a more detailed look at the mechanism, see our article on how nattokinase works at the molecular level.

3. Blood Pressure: What the Clinical Trials Found

Hypertension affects an estimated 1.28 billion adults globally and is one of the leading modifiable risk factors for cardiovascular events. Nattokinase's antihypertensive potential has been evaluated in several randomized controlled trials. The most frequently cited is a 2008 trial by Kim et al., published in Hypertension Research, which randomized 86 participants with untreated systolic blood pressure of 130–159 mmHg to 2,000 FU nattokinase or placebo for 8 weeks. The nattokinase group achieved approximately 5 mmHg reduction in systolic and 3 mmHg reduction in diastolic blood pressure compared to placebo — a clinically meaningful magnitude, given that a sustained 5 mmHg reduction in systolic pressure is associated with meaningfully lower cardiovascular event risk in population data.

A 2023 systematic review and meta-analysis pooled 6 RCTs with 546 total participants and confirmed reductions of 3.45 mmHg systolic and 2.32 mmHg diastolic (both p < 0.00001) versus placebo. The researchers concluded that nattokinase can serve as an effective adjunctive therapy for hypertension. The proposed mechanism involves nattokinase's inhibition of angiotensin-converting enzyme (ACE) and reduction of plasma angiotensin II levels — a pathway similar to that of ACE-inhibitor medications like lisinopril, though with a very different potency profile.

These blood pressure effects appear dose-dependent. The meta-analysis found that effects were more pronounced at doses exceeding 100 mg daily (equivalent to 2,000 FU or more). At doses below this threshold, results were inconsistent. Nattokinase should be understood as an adjunct to — not a replacement for — antihypertensive medications, particularly for those with stage 2 hypertension or above. Anyone already on blood pressure medications should consult their physician before adding nattokinase, as the additive effect on blood pressure could be clinically significant. For a more detailed breakdown of the hypertension research, see our article on nattokinase and blood pressure.

4. Atherosclerosis and Plaque: The 1,062-Participant Study

Atherosclerosis — the progressive narrowing of arteries due to plaque accumulation — is the underlying pathology behind most heart attacks and ischemic strokes. Reversing or slowing plaque progression is among the hardest things to achieve with any supplement; statins remain the gold standard for lipid-related plaque management, and their evidence base spans decades. Nattokinase research on plaque is comparatively young, but one study in particular has drawn significant attention.

Published in Frontiers in Cardiovascular Medicine in 2022, a clinical study of 1,062 participants examined nattokinase at two doses — 10,800 FU/day and 3,600 FU/day — over 12 months. At the higher dose, researchers measured significant reductions in carotid artery intima-media thickness (a standard marker of atherosclerosis progression) and carotid plaque size, with improvement rates ranging from 66.5% to 95.4% depending on participant characteristics. Notably, 3,600 FU/day showed no significant effect — a finding with direct implications for dosing decisions.

• Improvement rates of 66.5–95.4% in plaque size at 10,800 FU/day over 12 months
• 3,600 FU/day was found to be ineffective in this study for plaque and lipid outcomes
• Benefits were enhanced by co-administration of vitamin K2 and aspirin, and by regular exercise
• No adverse effects were recorded at 10,800 FU/day — consistent with nattokinase's general safety profile

It is important to flag that 10,800 FU/day is substantially higher than standard supplement doses (typically 2,000–4,000 FU/day). The clinically studied cardiovascular maintenance dose of 2,000 FU/day used in the blood pressure trials may not produce the same anti-atherosclerotic effects seen at higher doses. This is an area where the research is still evolving — and where speaking with a cardiologist before making dosing decisions is worthwhile. Also note that this study was conducted in participants with established atherosclerosis, not healthy individuals — the results may not translate to primary prevention contexts. Our article on nattokinase as a natural blood thinner covers related safety and interaction considerations.

5. Anti-Inflammatory and Antioxidant Effects on the Heart

Cardiovascular disease is not only a mechanical problem of blocked arteries — it is also an inflammatory one. Chronic low-grade inflammation drives endothelial dysfunction, accelerates plaque instability, and increases the risk of acute coronary events. Emerging research has begun to characterize nattokinase's activity on inflammatory pathways, adding a dimension to its cardiovascular profile that goes beyond its fibrinolytic mechanism.

A 2024 narrative review published in Expert Review of Cardiovascular Therapy summarized evidence that nattokinase modulates the NF-κB and Nrf2 signaling pathways — two of the central regulators of inflammatory and oxidative stress responses in vascular tissue. NF-κB activation drives production of pro-inflammatory cytokines; Nrf2 activation upregulates antioxidant defenses. Nattokinase appears to inhibit the former and activate the latter, at least in preclinical models. These findings have not yet been fully confirmed in large human trials, but they are mechanistically plausible and consistent with observations in animal studies.

A 2024 comparison of nattokinase and NOACs (non-vitamin K antagonist oral anticoagulants) published in Biomolecules highlighted that nattokinase's multi-target profile — combining fibrinolytic, antithrombotic, antihypertensive, and anti-inflammatory properties — differentiates it from single-mechanism pharmaceutical interventions. Synthetic anticoagulants like rivaroxaban address one specific step in the coagulation cascade; nattokinase acts across multiple cardiovascular risk pathways simultaneously. That said, the clinical significance of each individual mechanism at typical supplement doses has not been fully quantified in head-to-head human trials.

6. Limitations of the Research: What We Don't Know Yet

Responsible interpretation of the nattokinase research requires acknowledging what the current evidence does not yet establish. The blood pressure meta-analysis pooled 6 RCTs with 546 participants — a respectable evidence base for a supplement, but small by pharmaceutical standards. Most individual trials ran for 8–12 weeks, leaving open questions about long-term cardiovascular outcomes — the kind of data (reduced heart attacks, reduced strokes) that would be needed to definitively establish nattokinase as a cardioprotective agent. As of mid-2026, no large randomized outcome trial has reported those endpoints for nattokinase.

The 1,062-participant atherosclerosis study showed striking plaque results at 10,800 FU/day but has not been independently replicated at that dose. The 3,600 FU/day dose — the most commonly available supplement dose — was found ineffective in that study, raising questions about whether standard commercial doses produce anti-atherosclerotic benefit. Meanwhile, absorption research confirms that nattokinase is sensitive to stomach acid and must reach the small intestine intact to exert its effects — meaning the delivery format of any given product matters considerably, and bioavailability between products can vary.

There is also an important drug interaction consideration: nattokinase has blood-thinning properties and should not be combined with anticoagulant or antiplatelet medications (warfarin, aspirin, clopidogrel, direct oral anticoagulants) without physician supervision. For anyone with an existing cardiovascular condition or on prescription heart medications, physician consultation is essential before starting nattokinase. The full drug interaction profile is covered in our dedicated article on nattokinase as a natural blood thinner, and the nattokinase dosage guide covers clinical dose ranges in detail.

7. BioAbsorb Nattokinase — Delivery That Protects the Enzyme

Nattokinase's biggest delivery challenge is the stomach. As an alkaline serine protease, it is highly sensitive to the low pH of the gastric environment — research confirms that stomach acid can significantly degrade enzyme activity before nattokinase reaches the small intestine, where it needs to be absorbed. This is why the delivery mechanism of any nattokinase supplement is not a minor technical detail — it directly determines how much active enzyme reaches systemic circulation.

BioAbsorb Nattokinase uses DRcaps delayed-release veggie capsules — a delivery technology specifically designed to resist stomach acid and release contents in the small intestine, where absorption occurs. Unlike standard enteric-coated capsules, DRcaps are free of phthalates and plasticizers commonly found in conventional enteric coatings, which is a relevant consideration for health-conscious consumers. Each capsule delivers 100mg of nattokinase with a confirmed activity of 2,000 FU — consistent with the clinically studied dose range used in the blood pressure trials.

BioAbsorb Nattokinase is manufactured in a Canadian GMP-certified facility and is non-GMO, free of Vitamin K2 (an important distinction for anyone already supplementing K2 separately), and completely free of gluten, nuts, eggs, dairy, fish, shellfish, and all animal products. Each batch is third-party tested for potency (confirmed ≥2,000 FU per capsule), heavy metals, and microbial contaminants. A 180-day supply is available at $49.87 — approximately $0.28 per day — making it one of the more cost-effective options in a category where quality and transparency vary widely. As with all nattokinase supplementation, it is most appropriate as a long-term cardiovascular maintenance supplement taken daily on an empty stomach, under the guidance of a healthcare provider for anyone with existing cardiovascular conditions or on medications.

Frequently Asked Questions

Does nattokinase actually work for heart health, or is the evidence too weak?

The evidence is real but incomplete. Multiple randomized controlled trials have demonstrated meaningful reductions in blood pressure (up to 5 mmHg systolic in some studies), and a 2023 meta-analysis of 546 participants confirmed the blood pressure effect across 6 RCTs. The 1,062-participant atherosclerosis study showed striking plaque results at high doses. However, no large outcome trial has yet shown that nattokinase reduces heart attacks or strokes — that data gap means calling it "proven" to prevent cardiovascular events overstates what the evidence currently supports. The honest framing is: promising upstream effects on established cardiovascular risk factors, with long-term outcome data still pending.

What dose of nattokinase has been used in heart health research?

Blood pressure trials have primarily used 2,000–6,000 FU per day, with the foundational Kim et al. trial using 2,000 FU for 8 weeks. The large atherosclerosis study found 10,800 FU/day effective for plaque regression but 3,600 FU/day ineffective — suggesting significant dose-dependency for anti-atherosclerotic effects. A clinical dose range of 2,000–4,000 FU/day is generally cited for cardiovascular maintenance, with higher doses reserved for specific clinical contexts and typically involving physician oversight.

Can nattokinase replace statins or blood pressure medication?

No — and this is important. Statins have decades of large-scale outcome data supporting their use in reducing cardiovascular events, and prescription blood pressure medications have well-established efficacy profiles. Nattokinase should be understood as a potential complementary strategy, not a substitute. Anyone currently on statins, blood thinners, or antihypertensive medications should speak with their physician before adding nattokinase, as interactions — particularly additive blood-thinning effects — are possible.

Why does delivery method matter for nattokinase supplements?

Nattokinase is an enzyme that must survive the acidic environment of the stomach to be absorbed intact in the small intestine. Research confirms it is sensitive to pepsin and low pH, and that stomach acid can significantly degrade activity before the enzyme reaches the site of absorption. Delayed-release or enteric-coated capsules protect the enzyme from this degradation — which is why the delivery technology used by a supplement product is a meaningful quality differentiator, not just a marketing feature.

Is nattokinase safe for long-term use?

Short-term human trials at doses up to 10,800 FU/day have not reported serious adverse events. However, long-term safety data at high doses is limited. At 2,000 FU/day — the dose used in most blood pressure trials — the safety profile appears favourable in available studies. The primary safety concern is not direct toxicity but rather its anticoagulant-like activity: people taking blood thinners, those with bleeding disorders, or those scheduled for surgery should not take nattokinase without consulting their physician. See our detailed article on nattokinase side effects for the full safety profile.

How long does it take for nattokinase to have an effect on cardiovascular markers?

Blood pressure changes in the primary RCTs were observed over 8-week supplementation periods at 2,000 FU/day. A single-dose study found measurable fibrinolytic effects within 2–8 hours of ingestion, suggesting acute activity on coagulation parameters. Atherosclerosis outcomes in the large clinical study were measured over 12 months — consistent with the slow, cumulative nature of plaque changes. Nattokinase should be approached as a long-term cardiovascular maintenance strategy, not a fast-acting intervention.

Conclusion

The research on nattokinase and heart health is more substantial than many people realize — and more nuanced than many supplement brands acknowledge. Multiple randomized trials have documented clinically meaningful blood pressure reductions at 2,000 FU/day, a 2023 meta-analysis confirmed these findings across 546 participants, and a 1,062-participant study reported significant atherosclerosis benefit at higher doses. For those looking to support long-term cardiovascular health with a well-researched natural enzyme, BioAbsorb Nattokinase — 2,000 FU per DRcaps delayed-release capsule — offers a formulation aligned with the clinically studied dose range, transparent third-party testing, and a delivery mechanism designed to protect enzyme activity where it counts.

Research Sources

• Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine, Vol. 24(8) (2023). Meta-analysis of 6 RCTs (546 participants) confirming statistically significant reductions in systolic (−3.45 mmHg) and diastolic (−2.32 mmHg) blood pressure with nattokinase supplementation vs. placebo.
• Effective Management of Atherosclerosis Progress and Hyperlipidemia with Nattokinase: A Clinical Study with 1,062 Participants. Frontiers in Cardiovascular Medicine, Vol. 9 (2022). Large-scale clinical study demonstrating plaque regression rates of 66.5–95.4% at 10,800 FU/day over 12 months; 3,600 FU/day was ineffective; no adverse events recorded.
• Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases. Integrative Medicine Insights, Vol. 13 (2018). Comprehensive mechanism review covering nattokinase's PAI-1 inactivation, tPA enhancement, plasmin amplification, and platelet aggregation inhibition; fibrinolytic activity estimated at 4× that of plasmin.
• A Single-Dose of Oral Nattokinase Potentiates Thrombolysis and Anti-Coagulation Profiles. Scientific Reports, Vol. 5 (2015). Double-blind, placebo-controlled crossover study in 12 healthy men; single 2,000 FU dose measurably enhanced fibrinolysis and anti-coagulation parameters within hours of ingestion.
• Effects of Nattokinase on Blood Pressure: A Randomized, Controlled Trial. Hypertension Research, Vol. 31(8) (2008). Foundational RCT in 86 participants with untreated hypertension; 2,000 FU/day for 8 weeks produced approximately 5 mmHg systolic and 3 mmHg diastolic reduction vs. placebo.
• Nattokinase as an Adjuvant Therapeutic Strategy for Non-Communicable Diseases. Expert Review of Cardiovascular Therapy, Vol. 22(10) (2024). Narrative review covering nattokinase's fibrinolytic, antithrombotic, anti-inflammatory, and antioxidant properties; discusses NF-κB and Nrf2 pathway modulation.
• Comparative Cardioprotective Effectiveness: NOACs vs. Nattokinase — Bridging Basic Research to Clinical Findings. Biomolecules, Vol. 14(8) (2024). Comparison of nattokinase's multi-target cardiovascular profile versus single-mechanism NOACs; contextualizes nattokinase's role in a pharmacological landscape.
• Study on the Transport and Internalisation Mechanism of Dietary Supplement Nattokinase in the Small Intestine. PubMed-indexed (Epub 2023). Identified nattokinase as a moderately absorbed biomolecule whose enterocyte transport is energy- and time-dependent, supporting the rationale for delayed-release delivery formats.
• Cardiovascular Diseases Fact Sheet. World Health Organization (2024). CVD responsible for approximately 19.8 million deaths in 2022 — approximately 32% of all global deaths, 85% from heart attack and stroke.
• Nattokinase — Herb Information. Memorial Sloan Kettering Cancer Center (reviewed 2023). Clinical summary of nattokinase's fibrinolytic mechanism, PAI-1 inactivation pathway, estimated 4× fibrinolytic potency vs. plasmin, and drug interaction cautions.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.